Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia
K Šimoničová, Ľ Janotka, H Kavcová, Z Sulová… - Drug Resistance …, 2022 - Elsevier
Resistance to the hypomethylating agents (HMAs) 5-azacytidine (AZA) and 5-aza-2′-
deoxycytidine (DAC) represents a major obstacle in the treatment of elderly patients with
myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) which are not
suitable for hematopoietic stem cells transplantation. Approximately 50% of patients do not
respond to HMA treatment because of intrinsic (primary) resistance, while others could
acquire drug resistance during the repeated cycles of the treatment. To prevent, delay or …
deoxycytidine (DAC) represents a major obstacle in the treatment of elderly patients with
myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) which are not
suitable for hematopoietic stem cells transplantation. Approximately 50% of patients do not
respond to HMA treatment because of intrinsic (primary) resistance, while others could
acquire drug resistance during the repeated cycles of the treatment. To prevent, delay or …